Table GPSurvey-2. Lifetime prevalence of drug use (percentage) among young adults (15-34 years old) in nationwide surveys among the general population

	Country and geographical area	Ref.	Year	Sample size	Cannabis	Cocaine (a)	Amphet-amines (b)	Ecstasy (c)	Hallucin-ogens	LSD

	Belgium
	Vlanderen (Brussels excluded)	⁽¹⁾	1994	na	9.2	1.2	2.0	1.3
	French Community	⁽²⁾	1996-97	508	17.8
	French Community	⁽³⁾	1998-99	504	26.1
	French Community	⁽⁴⁾	2000	282	30.9
	National coverage (Flemish, Wallon and Brussels region)	⁽⁵⁾	2001	2758	19.2		4.0
	Czech Republic
	National	⁽¹⁾	2002	1002	38.0		4.3	8.8		4.7
	Denmark
	National	⁽¹⁾	1990	na	36.0
	National	⁽²⁾	1994	2521			4.0
	National	⁽³⁾	2000	4141	44.6	4.5	9.6	2.6	4.7	1.3
	Germany
	Western Germany	⁽¹⁾	1990	19207	14.5	1.3	2.7
	East Germany	⁽²⁾	1990	na	1.0	0.1	0.1
	Old Länder (W. Germany) and New Länder (E. Germany)	⁽³⁾	1995	3157	19.7	3.6	4.3	3.2	2.4
	Old Länder (W. Germany) and New Länder (E. Germany)	⁽⁴⁾	1997	3058	19.5	2.2	2.4	3.6	2.1
	National	⁽⁵⁾	2000	3017	30.8	4.0	3.4	3.7	4.1	2.4
	Estonia
	National	⁽¹⁾	1998	804	9.0	2.0	3.0	2.0		1.0
	Greece
	Athens	⁽¹⁾	1993	na	15.5	1.5	1.7
	Greece except Aegean and Ionian Islands	⁽²⁾	1998	2014	19.7	2.2	0.7	0.6	1.7
	Spain
	National	⁽¹⁾	1995	5813	22.9	5.9	4.0	3.5
	National	⁽²⁾	1997	6898	31.8	5.2	4.0	4.7	4.4
	National	⁽³⁾	1999	6293	28.5	4.8	3.2	4.4	2.9
	National	⁽⁴⁾	2001	6915	35.0	7.7	4.8	7.9	4.7
	France
	National	⁽¹⁾	1992	373
	Metropolitan France	⁽²⁾	1995	756	27.7	1.8	1.6		2.3
	National	⁽³⁾	1999	753	32.9	1.9	0.1	1.7	2.4	1.5
	National	⁽⁴⁾	2000	4749	35.7	1.9	1.4	1.8		2.0
	Metropolitan France	⁽⁵⁾	2002	730	39.9	3.0	0.1	1.9	3.0	1.5
	Ireland
	National	⁽¹⁾	1998	na	30.0
	National	⁽²⁾	1998	318	26.2
	National	⁽³⁾	2000	404	19.7
	National	⁽⁴⁾	2002-03		24.4	4.8	4.9	7.1		4.6
	Italy
	National	⁽¹⁾	2001	3698	24.5	4.0	1.4	2.6	1.8	0.0
	Latvia
	National	⁽¹⁾	2003		19.6	1.9	5.3	5.0	3.1	2.2
	Luxembourg
	National ( representative regional communities)	⁽¹⁾	1998	na	15.8	0.3		1.9	3.9	1.3
	Hungary
	National	⁽¹⁾	2001	790	13.0	1.3	3.6	4.5	3.1	3.1
	Netherlands
	National	⁽¹⁾	1997-98	9090	27.3	3.7	3.0	4.4	4.6	1.5
	National	⁽²⁾	2000-01	6687	31.5	5.1	5.1	7.4	6.4	1.6
	Poland
	National	⁽¹⁾	2002		14.7	1.3	4.1	1.5	1.3	2.5
	Portugal
	National	⁽¹⁾	2001	6406	12.4	1.3	0.6	1.4		0.6
	Slovakia
	National	⁽¹⁾	2002	1147	26.9	2.2	1.7	3.9	1.3
	Finland			1000
	National	⁽¹⁾	1992	974	10.1
	National	⁽²⁾	1996	615	15.0
	National	⁽³⁾	1998	1240	17.5	1.2	2.0	1.3		0.9
	National	⁽⁴⁾	2000		16.6	1.2	2.5	1.4		1.0
	National	⁽⁵⁾	2002		22.4	1.5	4.1	3.4		1.7
	Sweden
	National	⁽¹⁾	1994	310	9.1	0.3	2.9	0.0		0.8
	National	⁽²⁾	1996	476	11.7	1.2	3.5	0.7		0.0
	National	⁽³⁾	1998	542	15.5	0.9	2.6	0.5
	National	⁽⁴⁾	2000	575	14.0	0.8	2.1	0.6		0.0
	United Kingdom
	England and Wales	⁽¹⁾	1994	4329	31.6	3.4	12.4	4.7	12.5	7.4
	England and Wales	⁽²⁾	1996	4720	34.5	4.4	14.5	7.5	12.7	8.9
	England and Wales	⁽³⁾	1998	4112	39.5	5.8	17.2	8.2	13.5	9.1
	England and Wales	⁽⁴⁾	2000	4910	43.0	9.8	20.3	11.2	15.2	10.5
	England and Wales	⁽⁵⁾	2001-02	9006	42.2	8.7	18.0	11.8	11.9	8.3
	England and Wales	⁽⁶⁾	2002-03	8520	43.4	10.0	18.6	13.0	13.1	9.1
	Northern Ireland	⁽⁷⁾	2002-03	na	25.0	2.9	7.0	11.5	10.2	7.7
	Norway
	National	⁽¹⁾	1999	794	20.9	3.3	5.4	2.5

Notes:
(a) Cocaine any form.
(b) For Belgium National 2001 and for Metropolitan France 1995: amphetamine+ecstasy, for Denmark National 1994: hard drugs.
(c) For Spain: ecstasy and other designer drugs.
This table aims to present national surveys. Exceptionally some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimaties for whole countries (or big regions with urban and rural areas). Athens was included as reference point for 1993 survey.
In surveys with small sample sizes results should be interpreted with caution.
Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.
For methods and definitions see [Methods and definitions - Prevalence and patterns of drug use in the general population].
For survey methods see [Table GPSurvey-1 Part (ii) Survey methods].
Sources: See [Table GPSurvey-1 Part(iii) Sources].

Download